Gilead Sciences: Multiple Myeloma trials

The registry lists 13 Multiple Myeloma studies with Gilead Sciences as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 8Phase 2 6Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07887672Phase 3
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT04892446Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03318861Phase 1Results posted
• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06413498Phase 3
• Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruitingNCT05396885Phase 2
• Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT04155749Phase 1
• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
• Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
• A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple MyelomaTerminatedNCT01101594Phase 1/2
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
• Efficacy Study of CYT997 in Multiple MyelomaTerminatedNCT00664378Phase 2
• A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
• Phase I/II Study of hLL1 in Multiple MyelomaCompletedNCT00421525Phase 1/2